Skip to the page

Data / Drug companies / Hawaii Repack, Inc.

Hawaii Repack, Inc.: 91 products in the FDA NDC directory, labeler code 85534

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Hawaii Repack, Inc. (labeler code 85534) lists 91 products in the FDA National Drug Code Directory, covering 34 finished drugs by generic name. By type: 81 prescription drugs, 6 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 11, 2025.

The request: Watch Hawaii Repack, Inc. (FDA labeler code 85534): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
85534
Products in commercial distribution
91
Packages
359
Finished drugs by generic name
34
Prescription products
81
Over the counter products
2
Controlled substance products
Schedule III 1
Started marketing in the last 12 months
0
Products with a marketing end date set
3
Earliest marketing start
September 11, 1984
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)8087.9%
Bulk ingredients for compounding66.6%
Drugs for further processing22.2%
Over the counter monograph drugs22.2%
Authorized generics (NDA)11.1%

Products by type

TypeProductsShare
Prescription drugs8189%
Bulk ingredients66.6%
Drugs for further processing22.2%
Over the counter drugs22.2%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Capsule2224.2%
Tablet1920.9%
Tablet, film coated1213.2%
Capsule, delayed release77.7%
Kit66.6%
Powder, for suspension66.6%
Tablet, delayed release44.4%
Capsule, delayed release pellets33.3%
Powder22.2%
Tablet, orally disintegrating22.2%
Solution11.1%
Gel11.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Amitryptline hydrochloride85534-0002KitBulk ingredients for compoundingJune 11, 2025
Olu Pain Management85534-0102PatchOver the counter monograph drugsDecember 24, 2024
Famotidine85534-0092Tablet, film coatedGeneric drugs (ANDA)August 23, 2023
Diclofenac Epolamine85534-0034SystemAuthorized generics (NDA)November 18, 2022
Famotidine85534-0091Tablet, film coatedGeneric drugs (ANDA)July 8, 2022
Albuterol Sulfate85534-0039Aerosol, meteredGeneric drugs (ANDA)November 30, 2021
Baclofen85534-0004TabletGeneric drugs (ANDA)July 13, 2021
Methocarbamol85534-0021TabletGeneric drugs (ANDA)January 1, 2021
Celecoxib85534-0068CapsuleGeneric drugs (ANDA)December 3, 2020
Celecoxib85534-0067CapsuleGeneric drugs (ANDA)December 3, 2020
Celecoxib85534-0066CapsuleGeneric drugs (ANDA)December 3, 2020
Celecoxib85534-0015CapsuleGeneric drugs (ANDA)December 3, 2020
Aspirin 81 mg85534-0042Tablet, coatedOver the counter monograph drugsOctober 1, 2020
Ibuprofen85534-0013TabletGeneric drugs (ANDA)May 8, 2020
Ibuprofen85534-0012TabletGeneric drugs (ANDA)May 8, 2020
Ibuprofen85534-0011TabletGeneric drugs (ANDA)May 8, 2020
Naproxen85534-0058TabletGeneric drugs (ANDA)March 1, 2020
Naproxen85534-0024TabletGeneric drugs (ANDA)March 1, 2020
Naproxen85534-0023TabletGeneric drugs (ANDA)March 1, 2020
Methocarbamol85534-0057TabletGeneric drugs (ANDA)August 15, 2019
Methocarbamol85534-0022TabletGeneric drugs (ANDA)August 15, 2019
Duloxetine85534-0053Capsule, delayed releaseGeneric drugs (ANDA)March 25, 2019
Butalbital, Acetaminophen, Caffeine85534-0046TabletGeneric drugs (ANDA)March 5, 2019
Ciprofloxacin85534-0075SolutionGeneric drugs (ANDA)November 1, 2018
Diclofenac sodium85534-0127PowderDrugs for further processingJune 4, 2018

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.